Article
Medicine, General & Internal
Austin Feindt, Montserrat Lara-Velazquez, Ahmad Alkhasawneh, Dinesh Rao, Raafat Makary, Keith Dombrowski, Daryoush Tavanaiepour, Gazanfar Rahmathulla
Summary: This case report presents a 72-year-old female patient who had undergone renal transplant 11 years ago and developed progressively worsening headaches and confusion. Imaging revealed brain edema in the frontal and temporal lobes. Surgical biopsy confirmed a diagnosis of Polymorphic PTLD. Early diagnosis is crucial for patient survival with PTLD.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Mariam Markouli, Fauzia Ullah, Najiullah Omar, Anna Apostolopoulou, Puneet Dhillon, Panagiotis Diamantopoulos, Joshua Dower, Carmelo Gurnari, Sairah Ahmed, Danai Dima
Summary: PTLD is a severe complication with variable incidence and timing depending on factors related to patients, treatments, and transplants. The pathogenesis is complex, mainly associated with EBV infection and decreased T-cell immune surveillance due to immunosuppression. Treatment is based on histologic subtypes, but specific management guidelines are lacking due to limited clinical trials.
Article
Immunology
Guang-Qiang Meng, Jing-Shi Wang, Yi-Ni Wang, Na Wei, Zhao Wang
Summary: These findings suggest that rituximab-containing regimens are effective in treating EBV-HLH patients with predominately B cell infection, especially for eliminating EBV. However, the treatment may not be as effective for patients with T and NK cell predominated EBV infection.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Jwa Hoon Kim, Hyungwoo Cho, Heungsup Sung, Ah Ra Jung, Yoon Sei Lee, Sang-wook Lee, Jin-Sook Ryu, Eun Jin Chae, Kyoung Won Kim, Jooryung Huh, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh
Summary: This study suggests that positive plasma EBV DNA is a stronger predictor for survival prognosis in patients with PTLD-DLBCL after transplantation compared to EBER or WB EBV DNA positivity, indicating its significant unfavorable impact on progression-free survival and overall survival.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Masayo Yamamoto, Motohiro Shindo, Takuya Funayama, Chihiro Sumi, Takeshi Saito, Yasumichi Toki, Mayumi Hatayama, Ken-Ichi Imadome, Yusuke Mizukami, Toshikatsu Okumura
Summary: This article reports a case of late-onset EBV-related HLH after CBT for CAEBV. Late-onset EBV-related PTLD may be life-threatening.
Review
Medicine, General & Internal
Tatsuya Okamoto, Hideaki Okajima, Elena Yukie Uebayashi, Eri Ogawa, Yosuke Yamada, Katsutsugu Umeda, Hidefumi Hiramatsu, Etsurou Hatano
Summary: With the advancement of immunosuppressive strategies, liver transplantation outcomes have improved significantly in children. However, Epstein-Barr virus infection and post-transplant lymphoproliferative diseases (PTLD), such as malignant lymphoma, remain serious complications that contribute to morbidity and mortality. Recently, early diagnosis through quantitative PCR and PET-CT testing, as well as treatment with rituximab, have shown promising results in achieving long-term remission. However, determining the optimal immunosuppression protocol after PTLD remission and finding treatments for refractory PTLD (e.g., PTL-NOS) are still areas of focus.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Takeo Mukai, Kenji Waki
Summary: This article discusses the possibility of XLP in patients with EBV encephalitis and presents a case of a 3-year-old boy diagnosed with XLP. The evaluation revealed mutations in the SH2D1A gene for this patient. The article also mentions the abnormal findings in EEG and head MRI during the patient's admission.
CLINICAL CASE REPORTS
(2023)
Review
Infectious Diseases
Julian Lindsay, Jad Othman, Madeleine R. Heldman, Monica A. Slavin
Summary: Management of EBV PTLD involves complex measures such as risk stratification, preemptive therapy, and balancing treatment options. Experimental therapies like donor-derived multipathogen and EBV specific CTLs show promise in prevention and treatment of EBV PTLD.
CURRENT OPINION IN INFECTIOUS DISEASES
(2021)
Article
Pharmacology & Pharmacy
Hao Ji, Taihua Yang, Chunlai Li, Youwei Zhu, Zhigang Zheng, Jiaxu Zhang, Yuan Liu, Yijin Gao, Huimin Wu, Jinxing Jiang, Junekong Yong, Mengke Chen, Yuanjia Tang, Qiang Xia, Feng Xue
Summary: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after transplantation, with 80% of patients being positive for Epstein-Barr virus (EBV). However, monitoring EBV DNA load for preventing and diagnosing EBV-PTLD has limited accuracy. Therefore, there is an urgent need for new diagnostic molecular markers. This study discovered that BHRF1-1 and BART2-5p, elevated in EBV-PTLD patients, promote proliferation and suppress apoptosis. Mechanistically, they inhibit the tumor suppressor gene LZTS2 and activate the PI3K-AKT pathway. These findings suggest that BHRF1-1 and BART2-5p could serve as potential diagnostic markers and therapeutic targets for EBV-PTLD.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Oncology
Miriam Verdu-Bou, Gustavo Tapia, Agueda Hernandez-Rodriguez, Jose-Tomas Navarro
Summary: Epstein-Barr virus (EBV) plays a role in lymphomagenesis, particularly in populations with immunodeficiencies like people living with HIV (PLWH). The presence of EBV in these lymphomas affects their epidemiological, pathological, and clinical characteristics, as well as their prognosis. EBV, along with cooperation with HIV, mediates the pathogenic roles in lymphomas arising in PLWH.
Article
Oncology
Shoichi Kimura, Yumi Oshiro, Hiromi Iwasaki, Masanori Kadowaki, Masao Ogata, Tsutomu Daa, Toshifumi Sakata, Shigeto Kawauchi, Ziyao Wang, Yasushi Takamatsu, Morishige Takeshita
Summary: This study investigated the clinicopathological characteristics, Epstein-Barr virus (EBV) infection, genetic findings, therapeutic response, and prognostic factors in patients with iatrogenic immunodeficiency-associated T- and natural killer (NK)-cell lymphoproliferative disorders (TNK-LPDs) in rheumatoid arthritis (RA) patients. The results showed that TNK-LPDs typically occur in the early phase of RA and have poor prognostic factors.
Article
Clinical Neurology
Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Kazuki Taoka, Mariko Tanaka, Reiko Matsuura, Shota Tanaka, Nobuhito Saito
Summary: This is the first report documenting the development of other iatrogenic immunodeficiency-associated lymphoproliferative disorder (OIIA-LPD) during temozolomide therapy. Timely diagnosis of the disease and discontinuation of temozolomide were considered to be the preferred management. Close monitoring for relapse should be continued.
Article
Cell & Tissue Engineering
Julie Brault, Ronald J. Meis, Linhong Li, Ezekiel Bello, Taylor Liu, Colin L. Sweeney, Sherry M. Koontz, Kennichi Dowdell, Narda Theobald, Janet Lee, Cornell Allen, Aaron B. Clark, Juan C. Ravell, Michael J. Lenardo, Gary A. Dahl, Harry L. Malech, Suk See De Ravin
Summary: XMEN disease is caused by mutations in the MAGT1 gene, leading to increased susceptibility to EBV infection and N-linked glycosylation defect. Restoration of NKG2D expression by MAGT1 mRNA electroporation in XMEN patients can improve immune response and cytotoxic activity, potentially offering a short-term therapy option.
Article
Medicine, General & Internal
Masayo Yamamoto, Motohiro Shindo, Chihiro Sumi, Sho Igarashi, Takeshi Saito, Nodoka Tsukada, Yasumichi Toki, Mayumi Hatayama, Junki Inamura, Kazuya Sato, Yusuke Mizukami, Yoshihiro Torimoto, Toshikatsu Okumura
Summary: The case presented a 69-year-old male patient who developed acquired hemophilia A (AHA) during treatment for Epstein-Barr-virus-associated T/natural killer-cell lymphoproliferative disease (EBV-T/NK-LPD). The patient's AHA improved with higher dose prednisolone treatment, achieving complete remission after 13 months of low-dose prednisolone maintenance. It is speculated that EBV-infected and proliferating monoclonal NK cells might have modulated the immune system and produced autoantibodies against factor VIII, leading to the development of AHA in this patient with EBV-T/NK-LPD.
Article
Surgery
Masaki Yamada, Camila Macedo, Kevin Louis, Tiange Shi, Douglas Landsittel, Christina Nguyen, Masayoshi Shinjoh, Marian G. Michaels, Brian Feingold, George V. Mazariegos, Michael Green, Diana Metes
Summary: Chronic Epstein-Barr virus (EBV) infection is a significant problem after pediatric organ transplantation, especially in heart transplant recipients with high viral load. This study analyzed the immune characteristics of CD8(+)/CD4(+) T cells in pediatric heart, kidney, and liver transplant recipients, and identified distinct phenotypic and transcriptomic profiles in heart HVL carriers. The results suggest different incidences of EBV complications and provide insights for risk stratification and clinical management in different types of transplant recipients.
AMERICAN JOURNAL OF TRANSPLANTATION
(2023)
